Brokerage Firm Rating Update on Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX) : 9 brokerage houses believe that Becton Dickinson and Company (BDX) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Becton Dickinson and Company (BDX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 1.62.

Becton Dickinson and Company (BDX) : The highest short term price target forecast on Becton Dickinson and Company (BDX) is $200 and the lowest target price is $169. A total of 12 equity analysts are currently covering the company. The average price of all the analysts is $185 with a standard deviation of $9.29.


For the current week, the company shares have a recommendation consensus of Buy. Also, UBS maintains their rating on the shares of Becton Dickinson and Company (NYSE:BDX). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $195 per share from $182 per share. The rating by the firm was issued on August 5, 2016.

Becton Dickinson and Company (NYSE:BDX): The stock opened at $176.76 and touched an intraday high of $177.76 on Wednesday. During the day, the stock corrected to an intraday low of $176.005, however, the bulls stepped in and pushed the price higher to close in the green at $177.76 with a gain of 0.30% for the day. The total traded volume for the day was 728,570. The stock had closed at $177.22 in the previous trading session.

Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.